BRD0705

• Description :

  BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM) . BRD0705 can be used for acute myeloid leukemia (AML) research[1].

• Product Name Alternative :

  UK-116865

• UNSPSC :

  12352005

• Target :

  GSK-3

• Type :

  Reference compound

• Related Pathways :

  PI3K/Akt/mTOR; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/brd0705.html

• Purity :

  99.86

• Solubility :

  DMSO : 300 mg/mL (ultrasonic)

• Smiles :

  O=C1C2=C(N=C3C([C@]2(CC)C4=CC=CC=C4)=CNN3)CC(C)(C)C1

• Molecular Formula :

  C20H23N3O

• Molecular Weight :

  321.42

• References & Citations :

  [1]Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10 (431) . pii: eaam8460.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  GSK-3α; GSK-3β

• CAS Number :

  [2056261-41-5]